Veracyte Envisia Genomic Classifier Gets Medicare Coverage to Aid in Lung Disease Dx

NEW YORK (GenomeWeb) – Veracyte said today that Medicare administrative contractor Palmetto GBA MolDx has issued a final local coverage determination for use of its Envisia Genomic Classifier assay to clarify the diagnosis of patients with interstitial lung disease who are suspected of having idiopathic pulmonary fibrosis.